Pfizer's colorectal cancer combo therapy gains accelerated approval from FDA
Pfizer gains FDA accelerated approval for BRAFTOVI (encorafenib) with cetuximab and mFOLFOX6 to treat metastatic colorectal cancer with BRAF V600E mutation, based on Phase III BREAKWATER trial results showing 61% response rate. Approval contingent on further clinical benefits verification.
Highlighted Terms
Related News
Pfizer's colorectal cancer combo therapy gains accelerated approval from FDA
Pfizer gains FDA accelerated approval for BRAFTOVI (encorafenib) with cetuximab and mFOLFOX6 to treat metastatic colorectal cancer with BRAF V600E mutation, based on Phase III BREAKWATER trial results showing 61% response rate. Approval contingent on further clinical benefits verification.